Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1011)

VOLUNTARY ANNOUNCEMENT IN RELATION TO THE APPLICATION FOR REVOCATION OF THE FIRST ARBITRAL AWARD AND LITIGATION IN RESPECT OF THE EQUITY INTEREST IN BEIJING KANGCHEN BIOLOGICAL TECHNOLOGY CO., LIMITED

This announcement is made by China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide shareholders and potential investors of the Company with the latest progress regarding: (i) the Company's application to the People's Court for the revocation of the first arbitral award; and (ii) the litigation initiated with the People's Court by NT Pharma Pacific Company Limited ("**NT Pacific**"), a wholly-owned subsidiary of the Company, in respect of the equity interest in Beijing Kangchen Biological Technology Co., Limited (北京康辰生物科技有限公司) ("**Beijing Kangchen**").

I. BACKGROUND

Reference is made to the previous announcements published by the Company in relation to the disputes between the Company and Beijing Konruns Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 603590, together with its related parties, collectively referred to as the "**Konruns Parties**") regarding the transaction of the assets of "Miacalcic" (the "**Transaction**").

NT Pacific currently holds approximately 25.3% equity interest in Beijing Kangchen, with the remaining equity interest mainly held by the Konruns Parties. The Transaction was subject to performance guarantee terms for the period from 2021 to 2023, and all relevant performance undertakings were fully fulfilled.

The Konruns Parties subsequently initiated two arbitrations with the China International Economic and Trade Arbitration Commission ("**CIETAC**") in relation to the relevant arrangements of the Transaction. Among which, in respect of the first arbitration, CIETAC rendered the Arbitration Award [2026] CIETAC Beijing Arbitration No. 1519 on 17 July 2026 (the "**First Award**"), which ruled that the Company and the relevant jointly liable parties are required to pay liquidated damages, relevant fees and arbitration fee allocations in the aggregate amount of approximately RMB92,000,000. The Company has significant objections to the First Award, and published an announcement in relation to such award on 18 August 2026.

II. APPLICATION FOR REVOCATION OF THE FIRST AWARD

The Company has, in accordance with the relevant legal provisions of the PRC, submitted an application for the revocation of the First Award (the "**Revocation Application**") to the competent People's Court, requesting the People's Court to revoke the First Award in accordance with the law.

The Company considers that the First Award contains material errors in both the ascertainment of facts and the application of law, and falls under statutory circumstances for revocation. The Company has engaged a professional legal team to handle the Revocation Application. As at the date of this announcement, the Revocation Application has been submitted to the People's Court and is pending acceptance and hearing by the People's Court in accordance with the law. The First Award is currently still within the period during which an application for revocation may be filed in accordance with the law.

III. LITIGATION INITIATED IN RESPECT OF THE EQUITY INTEREST IN BEIJING KANGCHEN

NT Pacific considers that there are circumstances where the interests of minority shareholders have been prejudiced during the course of the operations of Beijing Kangchen; in respect of such circumstances and the rights and interests involved therein, NT Pacific has submitted an indictment to the competent People's Court in Beijing, the PRC, initiating litigation naming Beijing Kangchen as the defendant and Beijing Konruns Pharmaceutical Co., Ltd. as the third party, requesting the People's Court to order the defendant to mandatorily repurchase the approximately 25.3% equity interest in Beijing Kangchen held by NT Pacific (the "**Litigation**").

NT Pacific initiated the Litigation with a view to safeguarding the legitimate rights and interests of NT Pacific as a shareholder of Beijing Kangchen in accordance with the law. As at the date of this announcement, the Litigation has been submitted to the People's Court and is pending acceptance and hearing by the People's Court in accordance with the law.

IV. THE COMPANY'S POSITION

The Company hereby declares that the Group will unswervingly safeguard its legitimate rights and interests through all lawful means (including but not limited to continuing to advance the Revocation Application and the Litigation, defending against the arbitration and claims asserted by the Konruns Parties in accordance with the law, and taking all appropriate legal actions).

V. IMPACT ON THE COMPANY AND RISK WARNING

The Company will continue to assess the impact of the above matters on the Group in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), and will make further announcement(s) as and when appropriate. The Group's daily operations are maintained in a normal state**. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman and Executive Director

Hong Kong, 30 October 2026

As at the date of this announcement, the executive Directors of the Company are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.